Redeye states the report’s highlights were good AAR growth within the Cloud and good cost control, but sales and earnings were below expectations. Redeye believes the implied Q4 2023 figures point to a challenging start to 2024 in Binero’s ‘legacy’ business. Redeye believes Infrateq reduces the issuance risk but introduces short-term uncertainties. Redeye increases its net sales and EBITDA estimates between 175-320% and narrows its fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Binero Group - Transformational 2024

© Modular Finance, source Nordic Press Releases